Is XORTX Therapeutics Inc. Common Stock a good investment? XORTX Therapeutics Inc. Common Stock (XRTX) is currently trading at 0.3950 USD.
In terms of valuation, the stock trades at a P/E ratio of 10.08. This relatively low multiple may signal that XORTX Therapeutics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: XORTX Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is 0.80.
No, it does not currently pay a dividend.
XORTX Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.58.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
| Year | Total Dividends |
|---|---|
| ▸2014 |
0.00 USD
|
| Feb. 17, 2014 | 0.0001 |
| ▸2013 |
0.00 USD
|
| Nov. 1, 2013 | 0.0001 |
| July 30, 2013 | 0.0001 |
| May 2, 2013 | 0.0001 |
| ▸2012 |
0.00 USD
|
| Dec. 31, 2012 | 0.0001 |
| Oct. 30, 2012 | 0.0001 |
| Aug. 1, 2012 | 0.0001 |
| April 26, 2012 | 0.0001 |
| Feb. 29, 2012 | 0.0001 |
| ▸2011 |
0.00 USD
|
| Dec. 9, 2011 | 0.0001 |
| Aug. 26, 2011 | 0.0001 |
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 10, 2023 | 0.11 |
Community Discussion